Short answer
Becton Dickinson (BDX) filed its Q4 2025 10-Q quarterly report on Feb 9, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $5.3B (up 1.6% year over year) with net income of $382M.
Q4 2025 key financials · XBRL
- Revenue
- $5.3B
- +1.6% YoY
- Net income
- $382M
- +26.1% YoY
- Operating margin
- 10.5%
- EPS (diluted)
- $1.34
- +28.8% YoY
Source: XBRL data from the Becton Dickinson (BDX) Q4 2025 10-Q on SEC EDGAR. USD.
Becton Dickinson Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $5.252B, up 1.6% YoY from $5.168B, driven by 1.2% FX impact; U.S. revenue growth 2.6%, international revenue flat (+0.2%)
- Gross profit margin 45.9% vs 43.3% YoY; operating performance margin declined 1.3%; selling/admin expense 26.5% vs 25.5%; R&D expense 5.8% vs 6.6%
- Best segment: Interventional revenue $1.330B up 5.8%, segment margin 42.1% vs 44.6%; Worst segment: Life Sciences revenue down 8.3%, segment margin 20.8% vs 28.7%
- Operating cash flow $657M; cash/short-term investments $1.035B; repurchased $250M stock, paid $299M dividends; $2B planned for share repurchase next quarter
- Near-term headwinds: Tariffs increasing costs, VoBP in China reducing volumes, FDA regulatory uncertainties for Infusion Systems, ethylene oxide sterilization regulations
Risk Factors
- No material changes to risk factors from 2025 Annual Report
- Product liability and regulatory compliance risks from healthcare regulations remain significant
- Competitive pressures from new entrants and technology innovation continue to impact market share
- Supply chain disruptions and operational risks persist amid global uncertainty
- Currency fluctuations and debt service obligations continue to pose financial risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Becton Dickinson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.